» Articles » PMID: 18849185

SPARC in Cancer Biology: Its Role in Cancer Progression and Potential for Therapy

Overview
Date 2008 Oct 14
PMID 18849185
Citations 109
Authors
Affiliations
Soon will be listed here.
Abstract

The ability to effectively target a tumor to achieve complete regression and cure is the ultimate goal that drives our need to better understand tumor biology. Recently, SPARC has generated considerable interest as a multi-faceted protein that belongs to a family of matricellular proteins. It functions not only to modulate cell-cell and cell-matrix interactions, but its de-adhesive and growth inhibitory properties in non-transformed cells have led to studies to assess its role in cancer. Its divergent actions reflect the complexity of this protein, because in certain types of cancers, such as melanomas and gliomas, SPARC is associated with a highly aggressive tumor phenotype, while in others, mainly ovarian, neuroblastomas and colorectal cancers, SPARC may function as a tumor suppressor. Recent studies have also demonstrated a role for SPARC in sensitizing therapy-resistant cancers. Here, the role of SPARC in cancer progression and its potential application in cancer therapy is discussed.

Citing Articles

Novel transcripts of EMT driving the malignant transformation of oral submucous fibrosis.

Shetty S, Padam K, Sharma M, Kudva A, Patel P, Radhakrishnan R Sci Rep. 2025; 15(1):3294.

PMID: 39865173 PMC: 11770107. DOI: 10.1038/s41598-025-87790-2.


Human Plasma Proteomic Profile of Clonal Hematopoiesis.

Yu Z, Vromman A, Nguyen N, Schuermans A, Rentz T, Vellarikkal S bioRxiv. 2024; .

PMID: 39554199 PMC: 11565774. DOI: 10.1101/2023.07.25.550557.


Tumor-secreted LCN2 impairs gastric cancer progression via autocrine inhibition of the 24p3R/JNK/c-Jun/SPARC axis.

Huang Z, Li Y, Qian Y, Zhai E, Zhao Z, Zhang T Cell Death Dis. 2024; 15(10):756.

PMID: 39424639 PMC: 11489581. DOI: 10.1038/s41419-024-07153-z.


Expression and secretion of SPARC, FGF-21 and DCN in bovine muscle cells: Effects of age and differentiation.

Shira K, Thornton K, Murdoch B, Becker G, Chibisa G, Murdoch G PLoS One. 2024; 19(7):e0299975.

PMID: 38959242 PMC: 11221754. DOI: 10.1371/journal.pone.0299975.


Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer.

Liu Y, Fang S, Zhao R, Liu B, Jin Y, Li Q J Cancer Res Clin Oncol. 2024; 150(6):321.

PMID: 38914827 PMC: 11196321. DOI: 10.1007/s00432-024-05825-z.